4552 — JCR Pharmaceuticals Co Income Statement
0.000.00%
Last trade - 00:00
- ¥97bn
- ¥103bn
- ¥34bn
- 70
- 49
- 37
- 51
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 23,160 | 24,781 | 30,085 | 51,082 | 34,343 |
Cost of Revenue | |||||
Gross Profit | 16,275 | 16,880 | 22,273 | 40,621 | 25,457 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 18,295 | 21,406 | 21,646 | 32,255 | 29,388 |
Operating Profit | 4,865 | 3,375 | 8,439 | 18,827 | 4,955 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4,928 | 3,422 | 8,653 | 19,404 | 5,412 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,711 | 2,680 | 6,889 | 14,518 | 3,787 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 3,715 | 2,679 | 6,893 | 14,508 | 3,773 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3,715 | 2,678 | 6,892 | 14,507 | 3,772 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 30.8 | 20.8 | 54.5 | 123 | 30.4 |
Dividends per Share | |||||
Special Dividends per Share |